Results 1 to 10 of about 2,699 (106)

Analyzing the adverse events of NK-1 receptor antagonists: a pharmacovigilance study from the FAERS database [PDF]

Scientific Reports
Background NK-1 receptor antagonists (NK-1RAs) are proven to be successful in preventing chemotherapy-induced nausea and vomiting (CINV). The safety profile of NK-1RAs has not been systematically analyzed in the real world.
Hong Pan, Xiang Shi, Yiguo Jiang, Jiaqiang Wu, Li Shen   +4 more
doaj   +2 more sources

Syndrome of Inappropriate Secretion of Antidiuretic Hormone in a Dog With Meningoencephalitis of Unknown Etiology. [PDF]

Vet Med Sci
This report describes a case of syndrome of inappropriate antidiuretic hormone secretion (SIADH) in a Maltese with meningoencephalitis of unknown etiology (MUE). The dog was treated with water restriction and tolvaptan, a vasopressin receptor antagonist, which resulted in an improvement in hyponatremia.
Lee Y, Park J, Chae Y, Yun T, Kim H, Kang BT.   +5 more
europepmc   +2 more sources

Rare but relevant: MDMA and hyponatraemia. [PDF]

Addiction
Abstract Conventionally used for its stimulant, empathogenic and entactogenic effects, 3,4‐methylenedioxymethamphetamine (MDMA, ecstasy) is one of the most commonly used psychoactive drugs, specifically among young adults and in nightlife and recreational party contexts.
Garcia MR, Gomes NGM, Dias-da-Silva D.
europepmc   +2 more sources

Evaluation of the Effect of IL-1 Antagonists on Pituitary Function. [PDF]

Int J Endocrinol
Background Familial Mediterranean fever (FMF) is a hereditary autoinflammatory disease frequently observed in populations along the Eastern Mediterranean coast, characterized by recurrent fever, abdominal pain, and joint inflammation. The disease results from mutations in the MEFV gene, which plays a critical role in regulating IL‐1β secretion ...
Aktas Koc F, Sariakcali B, Sahin A.
europepmc   +2 more sources

Metabolic effects of vasopressin in pathophysiology of diabetic kidney disease

Frontiers in Endocrinology, 2023
The diabetic kidney disease (DKD) is the major cause of the chronic kidney disease (CKD). Enhanced plasma vasopressin (VP) levels have been associated with the pathophysiology of DKD and CKD.
Svetlana Lebedeva, Arus Margaryan, Elena Smolyarchuk, Andrey Nedorubov, Maria Materenchuk, Alexander Tonevitsky, Kerim Mutig, Kerim Mutig   +7 more
doaj   +1 more source

Clinical Implication of the Antidiuretic Hormone (ADH) Receptor Antagonist Mozavaptan Hydrochloride in Patients with Ectopic ADH Syndrome [PDF]

Japanese Journal of Clinical Oncology, 2010
Ectopic antidiuretic hormone syndrome is a medical emergency characterized by dilutional hyponatremia. Clinical effectiveness of the vasopressin V2 receptor antagonist mozavaptan was evaluated in 16 patients. In short-term (7-day) treatment with the drug, serum sodium concentration (mean ± standard deviation) significantly (P = 0.002) increased from ...
Ken, Yamaguchi, Noriharu, Shijubo, Tetsuro, Kodama, Kiyoshi, Mori, Takahiko, Sugiura, Takayuki, Kuriyama, Masaaki, Kawahara, Tetsu, Shinkai, Haruo, Iguchi, Masanori, Sakurai   +9 more
openaire   +2 more sources

Evidence for a Prehypertensive Water Dysregulation Affecting the Development of Hypertension: Results of Very Early Treatment of Vasopressin V1 and V2 Antagonism in Spontaneously Hypertensive Rats

Frontiers in Cardiovascular Medicine, 2022
In addition to long-term regulation of blood pressure (BP), in the kidney resides the initial trigger for hypertension development due to an altered capacity to excrete sodium and water.
Ignazio Verzicco, Stefano Tedeschi, Gallia Graiani, Alice Bongrani, Maria Luisa Carnevali, Simona Dancelli, Jessica Zappa, Silvia Mattei, Achiropita Bovino, Stefania Cavazzini, Rossana Rocco, Anna Calvi, Barbara Palladini, Riccardo Volpi, Valentina Cannone, Pietro Coghi, Alberico Borghetti, Aderville Cabassi   +17 more
doaj   +1 more source

Successful Long-Term Treatment of Hyponatremia in Syndrome of Inappropriate Antidiuretic Hormone Secretion with Satavaptan (SR121463B), an Orally Active Nonpeptide Vasopressin V2-Receptor Antagonist [PDF]

Clinical Journal of the American Society of Nephrology, 2006
The effects of satavaptan (SR121463B), a novel long-acting orally active vasopressin V(2)-receptor antagonist, were investigated in patients with the syndrome of inappropriate antidiuretic hormone secretion (SIADH). In the first part of this randomized, double-blind study, 34 patients first were treated with satavaptan (versus placebo) for up to 5 d ...
Alain, Soupart, Peter, Gross, Jean-Jacques, Legros, Sándor, Alföldi, Djillali, Annane, Hassan M, Heshmati, Guy, Decaux   +6 more
openaire   +2 more sources

Equivalent Efficacy and Decreased Rate of Overcorrection in Patients With Syndrome of Inappropriate Secretion of Antidiuretic Hormone Given Very Low-Dose Tolvaptan

Kidney Medicine, 2020
Rationale & Objective: Euvolemic hyponatremia often occurs due to the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Vasopressin 2 receptor antagonists may be used to treat SIADH.
Ramy M. Hanna, Juan Carlos Velez, Anjay Rastogi, Minhtri K. Nguyen, Mohammad K. Kamgar, Kyaw Moe, Farid Arman, Huma Hasnain, Niloofar Nobakht, Umut Selamet, Ira Kurtz   +10 more
doaj   +1 more source

Vasopressin and a Nonpeptide Antidiuretic Hormone Receptor Antagonist (OPC-31260)

Blood Pressure, 1994
The development of nonpeptide orally active AVP analogues has provided a new tool with which to assess the physiological and pathophysiological role of vasopressin (AVP). We have previously characterised the nonpeptide vasopressin V1 receptor antagonist OPC-21268, and now report the in vitro characterisation of the nonpeptide V2 receptor antagonist OPC-
L M, Burrell, P A, Phillips, J M, Stephenson, J, Risvanis, C I, Johnston   +4 more
openaire   +2 more sources